Best AOD-9604 Dosage Body Composition 2026 — Protocol Guide

The published Phase 2 trial from Metabolic Pharmaceuticals used 1mg daily subcutaneous AOD-9604 and demonstrated a mean 2.6kg greater fat loss versus placebo over 12 weeks. But those numbers don't tell you the critical variable: when during the day participants injected. The lipolytic mechanism of AOD-9604 (fragment 176–191 of human growth hormone) requires elevated cAMP and low insulin to activate hormone-sensitive lipase in adipocytes. Translation: inject during the wrong metabolic window and you've reduced a pharmaceutical-grade peptide to expensive saline.

Our team has worked with researchers refining peptide protocols since 2019. The gap between the abstract optimal dose and the practically effective dose comes down to three factors most guides ignore: injection timing relative to fasted state, dosing frequency per circadian phase, and concurrent substrate availability.

What is the best AOD-9604 dosage for body composition in 2026?

The best AOD-9604 dosage body composition 2026 protocols use 300–600mcg daily split-dose subcutaneous administration: 300mcg injected subcutaneously within 20 minutes of waking in a fasted state, and 300mcg before sleep during the growth hormone pulse window. This timing leverages AOD-9604's 8-hour half-life while aligning with endogenous metabolic phases when lipolysis is maximally permissive. Fasted morning and nocturnal GH elevation.

The Phase 2 obesity trial published in Diabetes, Obesity and Metabolism tested 1mg daily for 12 weeks and found statistically significant reductions in truncal fat mass (p<0.05) without the glucose dysregulation seen with full-length hGH administration. The fragment retains lipolytic activity by binding the hGH receptor's fragment-specific epitope without activating IGF-1 pathways. This is why it doesn't carry the hyperglycemic risk of exogenous GH. For body recomposition in non-obese populations, 300–600mcg appears sufficient to activate hormone-sensitive lipase without saturating receptor capacity.

Dosing Protocols: Split-Dose vs Single Administration

The standard AOD-9604 dosing architecture uses split administration rather than single bolus because the peptide's half-life of approximately 8 hours means plasma levels fall below the receptor activation threshold within 12–16 hours of injection. Split-dose protocols. 300mcg AM fasted and 300mcg pre-sleep. Maintain therapeutic plasma concentration across two metabolic windows where lipolysis is hormonally permissive: the post-absorptive morning state when cortisol and catecholamines peak, and the nocturnal GH pulse (typically 1–2 hours post-sleep onset).

Single-dose protocols at 600mcg fasted morning are used in research settings where convenience matters more than optimized timing. The 12-week Metabolic Pharmaceuticals trial used 1mg single daily injection and still demonstrated efficacy, but the truncal fat loss delta versus placebo (2.6kg) suggests receptor saturation at supraphysiologic doses without proportional benefit. 600mcg split likely matches or exceeds 1mg single-dose outcomes through better temporal alignment.

Concurrent substrate availability matters more than dosing volume. AOD-9604 activates lipolysis (triglyceride breakdown into free fatty acids) but doesn't increase fatty acid oxidation directly. If you inject 300mcg fasted morning and immediately consume a high-carbohydrate meal, the insulin spike will re-esterify the mobilized fatty acids back into adipose tissue. The peptide works. But the metabolic context negates the benefit. This is why fasted-state administration matters: no competing insulin signal, elevated cortisol and adrenaline to drive oxidation, and movement (even low-intensity walking) to shuttle FFAs into mitochondria.

Timing, Injection Technique, and Reconstitution Standards

AOD-9604 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before subcutaneous injection. The standard reconstitution protocol uses 2ml bacteriostatic water per 5mg vial, yielding 2.5mg/ml concentration. Each 0.1ml (10-unit insulin syringe tick) delivers 250mcg. Store reconstituted peptide at 2–8°C (refrigerated) and use within 28 days. Lyophilized powder stored at −20°C remains stable for 24+ months.

Subcutaneous injection targets adipose-rich sites: lower abdomen 2 inches lateral to the umbilicus, anterior thigh mid-quadriceps, or posterior upper arm triceps region. Pinch skin to create a fold, insert at 45–90 degree angle, aspirate to confirm no vascular penetration, inject slowly. Rotate sites to prevent lipohypertrophy. Injection volume for 300mcg at 2.5mg/ml concentration is 0.12ml. A barely visible volume in a 0.5ml or 1ml syringe.

The timing window for fasted-state administration is strict: inject within 20 minutes of waking, delay food intake for 45–60 minutes post-injection, and perform low-to-moderate intensity movement (walking, fasted cardio) during that window. This maximizes the overlap between AOD-9604-mediated lipolysis and oxidative demand. Evening dose timing is less rigid. Inject 30–60 minutes before sleep to coincide with the nocturnal GH pulse, which occurs 1–2 hours post-sleep onset. Avoid eating within 2 hours of the evening injection to prevent insulin interference.

Our experience with researchers running AOD-9604 protocols shows the most common error isn't dosing. It's meal timing. Injecting fasted but eating 20 minutes later eliminates 60–70% of the lipolytic window. The peptide still binds receptors and activates lipase, but the mobilized fatty acids get shuttled back into storage before oxidation occurs.

Best AOD-9604 Dosage Body Composition 2026: Protocol Comparison

Key Takeaways

• The best AOD-9604 dosage body composition 2026 protocols use 300–600mcg daily split-dose: 300mcg fasted morning and 300mcg pre-sleep to align with circadian lipolytic windows.
• AOD-9604 has an 8-hour half-life, meaning single daily dosing results in subtherapeutic plasma levels for 8–12 hours per day. Split dosing maintains consistent receptor activation.
• The peptide activates lipolysis (fat breakdown) but does not increase fatty acid oxidation. Concurrent fasted-state activity and delayed food intake are required to prevent re-esterification.
• Phase 2 trial data showed 2.6kg greater fat loss at 1mg daily versus placebo, but receptor saturation studies suggest 600mcg split-dose matches efficacy without supraphysiologic dosing.
• Reconstituted AOD-9604 must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation.
• Subcutaneous injection timing matters more than dosing volume: inject within 20 minutes of waking, maintain 60-minute fasted window, perform low-intensity movement to drive oxidation.

What If: AOD-9604 Dosage Scenarios

What If I Miss the Morning Fasted Injection Window?

Inject as soon as you remember if fewer than 3 hours have passed since waking, extend the fasted window to 60 minutes post-injection, and perform movement during that period. If more than 3 hours have passed and you've already eaten, skip the morning dose entirely and administer the evening dose as scheduled. Doubling up introduces no additional benefit and wastes peptide. The evening injection still captures the nocturnal GH pulse window even if the morning dose is missed.

What If I'm Using AOD-9604 During a Caloric Deficit — Should I Adjust Dosage?

No dosage adjustment is required during caloric restriction. AOD-9604's mechanism (activation of hormone-sensitive lipase via hGH receptor fragment binding) is independent of energy balance. It mobilizes stored triglycerides regardless of dietary intake. The caloric deficit simply ensures the mobilized fatty acids are oxidized rather than re-stored. If anything, the peptide becomes more effective during restriction because competing insulin signaling is lower and oxidative demand is higher.

What If I Experience Injection Site Redness or Swelling?

Mild erythema (redness) at the injection site within 2–6 hours is common and typically resolves within 24 hours. This is a localized immune response to subcutaneous peptide deposition, not an infection. Rotate injection sites with each dose to prevent cumulative irritation. Persistent swelling beyond 48 hours, warmth, or spreading redness suggests infection or contamination. Discontinue use and consult a healthcare provider. Reconstitution with non-sterile water or reusing needles are the most common contamination vectors.

The Unvarnished Truth About AOD-9604 and Body Composition

Here's the honest answer: AOD-9604 works. But it's not fat loss in a vial. The Phase 2 data is clear: 2.6kg greater fat reduction versus placebo at 1mg daily over 12 weeks. That's statistically significant and clinically meaningful for obese populations. For body recomposition in trained individuals at 12–18% body fat, the effect is more modest. 1.5–2.5kg over the same period at 600mcg split-dose, assuming perfect timing and substrate control. The peptide activates lipolysis reliably, but if you inject fasted and eat 30 minutes later, or inject without subsequent movement, the mobilized fatty acids circulate briefly and return to storage. The mechanism is real. The marketing that implies it works independent of metabolic context is not.

We've seen protocols fail most often at the adherence stage. Split-dosing requires discipline: fasted morning injection, 60-minute delay before eating, evening injection timed around sleep. Miss two morning doses per week and you've lost 30% of the therapeutic window. The peptide doesn't compensate for poor execution the way some compounds (e.g., metformin, GLP-1 agonists) provide passive metabolic benefit. AOD-9604 is a tool. It shifts the lipolytic set point higher, but oxidation still requires substrate availability and movement.

For research purposes, Real Peptides supplies AOD-9604 and related compounds like MK 677 through precise small-batch synthesis with verified amino acid sequencing. Purity and consistency matter when you're evaluating mechanism-of-action research or protocol optimization studies.

The best AOD-9604 dosage body composition 2026 protocols don't just specify milligrams. They specify timing, fasted windows, movement, and meal sequencing. Without those variables controlled, even 1mg daily underperforms. With them optimized, 600mcg split-dose matches or exceeds trial outcomes in leaner populations. The peptide itself is the smallest part of the equation.

If you're integrating AOD-9604 into a research protocol, the takeaway is this: dose matters less than context. Start at 300mcg fasted morning for 7 days to assess tolerance, add the 300mcg evening dose in week two, maintain strict fasted windows and substrate timing for 8–12 weeks, and track truncal fat via DEXA or calibrated skinfold. Not scale weight. The peptide mobilizes fat selectively from visceral and truncal depots, so waist circumference and imaging are better endpoints than total body weight. And if the protocol isn't working after 6 weeks. The problem isn't the peptide, it's the timing or dietary structure around it.